34 In the phase 2 setting, the triplet combination showed a trend toward improved PFS when compared to the placebo arm with dabrafenib/trametinib (16.0 months vs 10.3 months) though statistical significance had not been reached. 35 Fifty-eight percent of patients in the triplet arm experienced grade 3/4 toxicities compared with 27% in the doublet arm.
1
—
—